Ultragenyx Pharmaceutical (RARE) Receivables - Net (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Receivables - Net data on file, last reported at $121.0 million in Q1 2026.

• On a quarterly basis, Receivables - Net rose 22.42% year-over-year to $121.0 million in Q1 2026; TTM through Mar 2026 was $121.0 million, a 22.42% increase from a year earlier, with the FY2025 full-year figure at $158.0 million, up 29.51% from the prior year.
• Receivables - Net for Q1 2026 stood at $121.0 million, up from $1.0 million in the prior quarter.
• Over the last five years, Receivables - Net for RARE reached as high as $124.5 million in Q2 2025 and fell as low as $1.0 million in Q4 2025.
• Historically, Receivables - Net has averaged $74.7 million across 5 years, with a median of $79.3 million in 2023.
• Across the five-year window, Receivables - Net jumped 166.87% in 2023 and sank 99.18% in 2025, its largest moves.
• Year by year, Receivables - Net stood at $27.5 million in 2022, then soared by 166.87% to $73.4 million in 2023, then jumped by 66.24% to $122.0 million in 2024, then sank by 99.18% to $1.0 million in 2025, then jumped by 12000.0% to $121.0 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $121.0 million in Q1 2026, $1.0 million in Q4 2025, and $112.5 million in Q3 2025.